3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Conditions
Testicular Neoplasms
1
Stomach Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Neoplasms, Unknown Primary
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Glioblastoma
1
Death
1
Colonic Neoplasms
1
Interventions
Oxaliplatin
200
Capecitabine
116
S 1 (combination)
106
Fluorouracil
105
Docetaxel
100
Cisplatin
88
Leucovorin
75
Paclitaxel
71
Irinotecan
68
apatinib
43
sintilimab
42
Drug Therapy
42
Surgical Procedures, Operative
37
Hyperthermic Intraperitoneal Chemotherapy
34
pembrolizumab
32
Radiotherapy
31
Trastuzumab
30
Gastrectomy
23
Nivolumab
22
Epirubicin
22
Tegafur
21
Bevacizumab
21
XELOX
20
titanium silicide
19
camrelizumab
19
tislelizumab
17
Ramucirumab
17
Carboplatin
16
Neoadjuvant Therapy
15
Endoscopic Mucosal Resection
15
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Stomach Neoplasms
×
erythromycin propionate-N-acetylcysteinate
×
Clear all
NCT02966509
2018-10-31
EPAC
Stanford University
Phase NA
Completed
213 enrolled
20 charts